Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-19.18%
↓ 237% below average
Average (22q)
13.95%
Historical baseline
Range
High:280.99%
Low:-74.78%
Volatility
2549.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -19.18% |
| Q2 2025 | -19.77% |
| Q1 2025 | -10.73% |
| Q4 2024 | 23.21% |
| Q3 2024 | -1.89% |
| Q2 2024 | -6.75% |
| Q1 2024 | 3.74% |
| Q4 2023 | 4.07% |
| Q3 2023 | -5.52% |
| Q2 2023 | 5.26% |
| Q1 2023 | 20.25% |
| Q4 2022 | -8.22% |
| Q3 2022 | -5.58% |
| Q2 2022 | 17.45% |
| Q1 2022 | 114.82% |
| Q4 2021 | -51.34% |
| Q3 2021 | -32.32% |
| Q2 2021 | 62.60% |
| Q1 2021 | -18.60% |
| Q4 2020 | 43.22% |
| Q3 2020 | -74.78% |
| Q2 2020 | 280.99% |
| Q1 2020 | 0.00% |